Active substanceMupirocinMupirocin
Similar drugsTo uncover
  • Bactroban®
    ointment externally 
  • Bactroban®
    ointment nazal. 
  • Bonderm
    ointment externally 
  • Supirocin®
    ointment externally 
  • Dosage form: & nbspMfor external use.
    Composition:

    In 100 g of ointment contains:

    Active substance: Mupirocin - 2 g.

    Excipients: macrogol 400 (polyethylene glycol 400), macrogol 4000 (polyethylene glycol 4000).

    Description:ABOUTwhite ointment.
    Pharmacotherapeutic group:antibiotic
    ATX: & nbsp

    D.06.A.X.09   Mupirocin

    Pharmacodynamics:

    Mupirocin - antibiotic produced by a microorganism Pseudomonas fluorescens. Mupirocin suppresses the synthesis of the bacterial cell protein through reversible binding to isoleucyl-transport RNA synthetase, which prevents the inclusion of isoleukin in the protein chains under construction. When used in minimal inhibitory concentrations mupirocin has bacteriostatic, and in higher concentrations - bactericidal action.

    Due to a specific mechanism of action and a unique chemical structure, there is no cross-resistance with other antibiotics.

    With the correct application of mupirocin, the risk of the emergence of resistant strains of microorganisms is small.

    Spectrum of antibacterial activity in vitro:

    Gram-positive aerobes:

    Staphylococcus aureus (including strains resistant to methicillin and producing beta-lactamases),

    Staphylococcus epidermidis,

    Staphylococcus species,

    Coagulase-negative Staphylococcus;

    Gram-negative anaerobes:

    Haemophilus influenzae,

    Neisseria gonorrhoeae,

    Neisseria meningitidis,

    Branhamella catarrhalis,

    Pasteurella multocida,

    Proteus mirabilis,

    Proteus vulgaris,

    Enterobacter cloacae,

    Enterobacter aerogenes,

    Citrobacter freundii,

    Bordetella pertussis;

    Insensitive:

    Corynebacterium species,

    Enterobacteriaceae,

    Gram-negative non-fermenting sticks,

    Micrococcus.

    Pharmacokinetics:

    Mupirocin practically does not penetrate through undamaged skin. In the case of adsorption through damaged skin, it is metabolized to a microbiologically inactive metabolite - monic acid - and quickly excreted by the kidneys.

    Indications:

    Primary and secondary infectious skin lesions caused by microorganisms susceptible to mupirocin, including:

    primary skin infections:

    • impetigo,
    • folliculitis,
    • furunculosis (including furuncles of the external auditory canal and auricle),
    • ecthyma;
    secondary infections:

    • infected eczema,
    • infected injuries (abrasions, insect bites, wounds, burns).

    Contraindications:

    Hypersensitivity to any component of the drug, children under 3 years.

    Carefully:

    Macrogol - polyethylene glycol - can be absorbed through the wound surface or through other skin lesions and excreted by the kidneys.

    Ointments based on macrogol can not be used on extensive surfaces in conditions accompanied by increased absorption of polyethylene glycol, and especially with moderate and severe renal failure.

    Pregnancy and lactation:

    Currently, there is insufficient data on the use of mupirocin in pregnancy, so the use of the drug is possible if the expected benefit exceeds the possible risk of complications.

    Removal of the drug in breast milk is unlikely, however, the use of the drug during lactation is possible if the expected benefit exceeds the possible risk of complications.

    Dosing and Administration:

    A small amount of mupirocin is applied to the affected surface of the skin. A bandage can be applied from above.

    After applying the product on the skin, you should thoroughly wash your hands.

    Apply 2-3 times a day for up to 10 days, depending on the severity of the lesion.
    In the absence of clinical effect within 3-5 days, it is recommended to revise the diagnosis and treatment tactics.

    Impaired liver function

    No correction is required.

    Renal impairment

    See "With caution".

    Older patients: restrictions are not required. Also see the "Caution" section.

    Side effects:

    Supirocin® ointment is well tolerated.

    Very rarely there is burning, itching at the site of application.

    Less than 1% of cases can be observed erythema, dry skin, edema, contact dermatitis.

    Skin allergic reactions (edema at the site of application, rash) on mupirocin or the basis of the ointment was rarely observed. When applying Supirosin ® ointment, in single cases it was reported about generalized allergic reactions.

    Overdose:

    No data.

    Interaction:

    Not reported.

    Ointment Supirocin® can not be combined with other topical preparations due to the risk of dilution, which is manifested by a decrease in antibacterial activity and a potential loss of stability.

    Special instructions:

    Do not apply to mucous membranes and in the drainage area. Avoid contact with ointment in the eyes. In case of contact, rinse thoroughly with water until all residual ointments are removed.

    In rare cases of allergic reactions or significant irritation of the skin with application of the Supiurocin® ointment, treatment should be stopped, the affected area should be rinsed with water to remove residual ointments and an alternative antibiotic therapy.

    As with other antibacterial drugs, the long-term administration of the ointment of Supirocin® can lead to an excessive growth of insensitive microorganisms.

    Effect on the ability to drive transp. cf. and fur:There was no adverse effect on the ability to drive / operate machinery.
    Form release / dosage:

    Ointment for local and external use, 2%.

    Packaging:

    For 15 grams in aluminum tubes, internally lacquered with latex, having a nozzle with a closed end, with a lid having a point for piercing.

    One tube together with the instruction for use is placed in a cardboard box.

    Storage conditions:

    In a dry, dark place at a temperature of no higher than 25 ° C. Do not freeze.

    Keep out of the reach of children.

    Shelf life:2 years.
    Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-000592/09
    Date of registration:29.01.2009
    Expiration Date:Unlimited
    The owner of the registration certificate:Glenmark Pharmaceuticals Co., Ltd.Glenmark Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspGLENMARK IMPEX LLCGLENMARK IMPEX LLCRussia
    Information update date: & nbsp04.09.2016
    Illustrated instructions
      Instructions
      Up